IDEXX Laboratories, Inc.
NASDAQ:IDXXMedical - Diagnostics & Research
+$12.33 today
- Market cap
- $55.03B
- Beta
- 1.54
- P/E (TTM)
- 40.8
- EPS (TTM)
- $13.67
Volume 0.37M
Average 0.58M
IDXX Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
IDEXX Laboratories, Inc.NASDAQ: IDXX
Depreciation & Amortization · Q3 FY2026 · quarter ended Sep 2026
Depreciation & amortization outflow shrinks to $0
Q3 FY2026 depreciation & amortization was $0, compared with $36.63M a year earlier. Trailing-twelve-month depreciation & amortization was $117.46M. Over 3 fiscal years it compounded at +9.1% a year.
Context
- Depreciation & amortization amounted to 3.4% of revenue in FY2025, unchanged from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly depreciation & amortization holds near $0 or moves back toward the trailing-twelve-month quarterly average of $29.36M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 145.18M USD
- Year-over-year change
- +11.7%
- 4-year CAGR
- +8.5%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 145.18M | +11.7% |
| FY2024 | 2024-12-31 | 129.94M | +13.1% |
| FY2023 | 2023-12-31 | 114.91M | +2.7% |
| FY2022 | 2022-12-31 | 111.9M | +7.0% |
| FY2021 | 2021-12-31 | 104.6M | — |
Depreciation & Amortization vs competitors
How IDXX compares with its peers on the latest reported figures
- IDXX's LTM Sep 2026 depreciation & amortization of $117.46M is the smallest of the 5 companies compared; the peer median is $588.5M.
- Its year-over-year change of -16.2% is the lowest of 5, against a peer median of +1.5%.
- Depreciation & amortization amounts to 2.5% of revenue for IDXX, versus a peer median of 11.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $6.72B | +45.9% | +14.3% | 10.1% | |
| LTM Sep 2026 | $694M | +3.6% | -0.1% | 13.5% | |
| LTM Jun 2026 | $483M | -0.6% | +1.6% | 5.1% | |
| LTM Aug 2026 | $117.65M | -5.8% | +8.7% | 13.3% | |
| LTM Sep 2026 | $117.46M | -16.2% | +9.1% | 2.5% | |
| Peer median (excluding IDXX) | $588.5M | +1.5% | +5.1% | 11.7% | |
Competitors are the stored peer set for IDXX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 744.84M | 679.09M | 845.04M | 887.87M | 1.06B |
| Depreciation & Amortization | 104.6M | 111.9M | 114.91M | 129.94M | 145.18M |
| Deferred Income Tax | (3.38M) | (35.07M) | (48.31M) | (24.19M) | 131.2M |
| Stock-Based Compensation | 37.76M | 49.77M | 59.74M | 60.3M | 0 |
| Change in Working Capital | (137.52M) | (273.53M) | (72.43M) | (133.24M) | (227.51M) |
| Accounts Receivables | (33.14M) | (41.4M) | (53.87M) | (28.28M) | (68.72M) |
| Inventory | (52.92M) | (121.73M) | (28.65M) | (28M) | (789K) |
| Accounts Payables | 11.23M | 3.47M | (557K) | 8.09M | (8.57M) |
| Other Working Capital | (62.7M) | (113.87M) | 10.65M | (85.04M) | (149.43M) |
| Other Non-Cash Items | 9.25M | 10.82M | 7.56M | 8.34M | 69.73M |
| Operating Cash Flow | 755.55M | 542.98M | 906.51M | 929M | 1.18B |
| Capital Expenditures | (119.55M) | (148.84M) | (133.63M) | (130.92M) | (124.68M) |
| Acquisitions (Net) | (173.42M) | (46.51M) | 0 | (77.7M) | 0 |
| Purchases of Investments | 0 | (25M) | 0 | 0 | (756K) |
| Sales of Investments | 0 | 71.51M | 0 | 1.56M | 0 |
| Other Investing Activities | 0 | (46.51M) | 8.38M | (10M) | 2.74M |
| Investing Cash Flow | (292.97M) | (195.35M) | (125.25M) | (207.06M) | (136.24M) |
| Debt Repayment | 23.5M | 430.5M | (404M) | (75M) | (30.39M) |
| Common Stock Issued | 46.57M | 35.75M | 47.03M | 44.49M | 93.36M |
| Common Stock Repurchased | (746.78M) | (819.71M) | (71.92M) | (837.03M) | (1.22B) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (20.7M) | (17.04M) | (13.11M) | (10.53M) | (7.24M) |
| Financing Cash Flow | (697.41M) | (370.94M) | (442M) | (878.07M) | (1.16B) |
| Effect of Forex Changes | (4.64M) | (8.61M) | 2.13M | (9.53M) | 11.2M |
| Net Change in Cash | (239.47M) | (31.91M) | 341.39M | (165.67M) | (108.2M) |
| Free Cash Flow | 636M | 394.15M | 772.88M | 798.08M | 1.05B |
IDEXX Laboratories, Inc.
NASDAQ:IDXX
Intrinsic Alpha fair value
Locked
Current Price
$698.47
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.